Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.044
- Book/Share 16.3757
- PB 1.4941
- Debt/Equity 0.665
- CurrentRatio 1.2822
- ROIC 0.1065
- MktCap 138674407193.0
- FreeCF/Share 1.8252
- PFCF 13.3649
- PE 14.1184
- Debt/Assets 0.2957
- DivYield 0.0705
- ROE 0.1091
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Pfizer Inc. (PFE) M&A Call Transcript
Published: September 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (NYSE:PFE ) M&A Call September 22, 2025 8:00 AM EDT Company Participants Francesca DeMartino - Chief Investor Relations Officer Chris Boshoff - Chief Scientific Officer and President of Research & Development Andrew Baum - Chief Strategy & Innovation Officer, Executive VP Jim List Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Umer Raffat - Evercore ISI Institutional Equities, Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Christopher Schott - JPMorgan Chase & Co, …
Read More
Johnson Fistel Investigates Fairness of Proposed Sale of Metsera
Published: September 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE).
Read More
Pfizer Stock Higher on Multi-Billion Dollar Metsera Buyout
Published: September 22, 2025 by: Schaeffers Research
Sentiment: Positive
Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion.
Read More
Pfizer acquires Metsera in $7.3B deal to boost obesity drug pipeline
Published: September 22, 2025 by: Proactive Investors
Sentiment: Positive
Pfizer Inc (NYSE:PFE, ETR:PFE) on Monday announced that it will acquire Metsera, Inc (NASDAQ: MTSR), a weight-loss drug developer, in a deal valued at up to $7.3 billion, or $47.50 per share in cash. Metsera is also eligible to receive an additional $22.50 per share contingent on the achievement of certain performance milestones.
Read More
Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal
Published: September 22, 2025 by: Investopedia
Sentiment: Positive
Metsera (MTSR) shares skyrocketed 60% in premarket trading after Pfizer (PFE) agreed to purchase the biopharma firm for up to $7.3 billion to jump into the lucrative weight-loss drug segment. Shares of Pfizer were up slightly.
Read More
Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal
Published: September 22, 2025 by: Benzinga
Sentiment: Positive
Pfizer Inc. PFE on Monday agreed to acquire Metsera, Inc. MTSR to accelerate the next generation of medicines for obesity and cardiometabolic diseases.
Read More
Mizuho's Jared Holz: There's not much value left in vaccine stocks
Published: September 19, 2025 by: CNBC Television
Sentiment: Negative
Jared Holz, Mizuho healthcare senior strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on pharmaceuticals, what new government vaccine panel recommendations mean for the stocks, and much more.
Read More
PFE vs. AZN: Which Cancer-Focused Drug Giant Is the Better Pick?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Negative
AstraZeneca and Pfizer both boast strong oncology pipelines, but growth paths, dividends and challenges set them apart for investors.
Read More
COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Negative
MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.
Read More
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500
Published: September 12, 2025 by: Seeking Alpha
Sentiment: Positive
Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 dividend 'dogs' could deliver 20.45% to 38.5% net gains by September 2026, with an average gain of 27.35%. Stocks like Amcor, Healthpeak, Conagra, Pfizer, and Verizon offer the best combination of high yield and low price, following the O'Higgins 'Dogs of the Dow' strategy.
Read More
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Published: September 12, 2025 by: Market Watch
Sentiment: Negative
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
Read More
Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots
Published: September 12, 2025 by: CNBC
Sentiment: Negative
Shares of Pfizer and Moderna fell on Friday after a report that Trump administration health officials plan to link Covid vaccines to the deaths of 25 children. The report comes as Health and Human Services Secretary Robert F.
Read More
Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer's late-stage pipeline, from oncology blockbusters to mRNA vaccines, positions it for long-term growth despite recent setbacks.
Read More
Pfizer's Comeback Accelerates
Published: September 11, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion, driven by Abrysvo RSV vaccine and Seagen-acquired oncology assets. Management expects over $20 billion in risk-adjusted revenue from new launches by 2030, offsetting $17–$20 billion in patent expirations. R&D investment of ~$11 billion in 2025 supports 28 Phase 3 programs across oncology, vaccines, inflammation, and rare diseases.
Read More
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Negative
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
3 Undervalued Dividend Stocks to Buy This September
Published: September 09, 2025 by: 24/7 Wall Street
Sentiment: Positive
Who doesn't love passive income? As investors, we love dividend stocks, especially the ones that have high yields since they provide a steady source of income and improve the total return potential.
Read More
Scoop Up These 3 Bargain-Bin Dividend Stocks
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Positive
Today, we'll be highlighting PFE, YORW, and UPS. The trio offers a market-crushing 5.8% yield, an A- blended S&P credit rating, and is trading 21% below fair value estimates. Pfizer appears to have the product portfolio and pipeline to return to modest growth. The York Water Company's capex spending and bolt-on acquisitions can fuel future growth.
Read More
Pfizer: Still A Bargain Despite Kennedy's Anti-Vaccine Attacks
Published: September 05, 2025 by: Seeking Alpha
Sentiment: Positive
Despite pressure from HHS Secretary RFK Jr. and pessimism from retail investors, Pfizer Inc.'s COVID-19 franchise sales were $808 million in Q2 2025, up 81.2% year-on-year. In addition, its oncology and tafamidis franchises once again helped Pfizer beat Wall Street analysts' expectations with wide margins. On the other hand, my fears that the launch of its next-generation drugs would be somewhat subdued were not realized.
Read More
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (September 2025)
Published: September 04, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Shares of Pfizer ( NYSE: PFE ) gained 4.50% over the past month after losing 6.50% the month prior.
Read More
Want $5,000 a Year In Passive Income? Buy These 3 Dividend Stocks and Hold for 5 Years
Published: September 04, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors looking to create meaningful passive income streams for retirement have a number of considerations to keep in mind.
Read More
Pfizer defends COVID-19 vaccine effectiveness after Trump remarks
Published: September 03, 2025 by: Reuters
Sentiment: Neutral
Pfizer on Wednesday defended the effectiveness of its COVID-19 vaccine, saying it has saved more than 14 million lives worldwide, after U.S. President Donald Trump urged pharmaceutical companies to justify the success of their pandemic drugs.
Read More
Pfizer's Golden Cross Signals Strength: How to Play the Stock
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.
Read More
7 Big Yields From The Beat-Up Healthcare Sector
Published: September 01, 2025 by: Forbes
Sentiment: Neutral
Healthcare stocks haven't moved since the April lows. As contrarian investors, this neglect piques our interest.
Read More
Trump tells drugmakers to 'justify the success' of Covid meds after FDA limits vaccine approval
Published: September 01, 2025 by: CNBC
Sentiment: Negative
President Donald Trump called on pharmaceutical companies to "justify the success" of their Covid drugs days after the FDA set new limits on who can receive vaccines for the virus. Trump last week fired Centers for Disease Control and Prevention's Director Susan Monarez after she refused to resign.
Read More
FDA Approves Updated COVID-19 Vaccines but With Restrictions
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.
Read More
Pfizer: At $25 Is PFE Stock Deep Value Or A Falling Knife?
Published: August 28, 2025 by: Forbes
Sentiment: Positive
After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a post-pandemic environment with normalized COVID-19 vaccine demand, its solid fundamentals and a compelling 6.9% dividend yield point to an interesting opportunity for long-term, risk-adjusted returns.
Read More
Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.
Read More
Pfizer: A 6% Dividend Yield That Pays You To Stay Defensive
Published: August 28, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer is deeply undervalued, trading at a multi-year low with a 6.65% dividend yield, making it a compelling long-term opportunity. Recent double-digit earnings growth, strong margins, and cost optimization efforts support my $33 price target and Strong Buy rating. Valuation metrics show Pfizer is significantly cheaper than peers, with limited downside risk and a stable, high-quality business model.
Read More
Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
Published: August 27, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts the.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000